RT Journal Article
SR Electronic
T1 The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.23.20026690
DO 10.1101/2020.02.23.20026690
A1 Liao, Minfeng
A1 Liu, Yang
A1 Yuan, Jin
A1 Wen, Yanling
A1 Xu, Gang
A1 Zhao, Juanjuan
A1 Chen, Lin
A1 Li, Jinxiu
A1 Wang, Xin
A1 Wang, Fuxiang
A1 Liu, Lei
A1 Zhang, Shuye
A1 Zhang, Zheng
YR 2020
UL http://medrxiv.org/content/early/2020/02/26/2020.02.23.20026690.abstract
AB The novel coronavirus SARS-CoV-2, etiological agent of recently named Coronavirus infected disease (COVID-19) by WHO, has caused more than 2, 000 deaths worldwide since its emergency in Wuhan City, Hubei province, China, in December, 2019. The symptoms of COVID-19 varied from modest, mild to acute respiratory distress syndrome (ARDS), and the latter of which is generally associated with deregulated immune cytokine production; however, we currently know little as to the interplay between the extent of clinical symptoms and the compositions of lung immune microenvironment. Here, we comprehensively characterized the lung immune microenvironment with the bronchoalveolar lavage fluid (BALF) from 3 severe and 3 mild COVID-19 patients and 8 previously reported healthy lung controls through single-cell RNA sequence (scRNA-seq) combined with TCR-seq. Our data shows that monocyte-derived FCN1+ macrophages, whereas notFABP4+ alveolar macrophages that represent a predominant macrophage subset in BALF from patients with mild diseases, overwhelm in the severely damaged lungs from patients with ARDS. These cells are highly inflammatory and enormous chemokine producers implicated in cytokine storm. Furthermore, the formation of tissue resident, highly expanded clonal CD8+ T cells in the lung microenvironment of mild symptom patients suggests a robust adaptive immune response connected to a better control of COVID-19. This study first reported the cellular atlas of lung bronchoalveolar immune microenvironment in COVID-19 patients at the single-cell resolution, and unveiled the potential immune mechanisms underlying disease progression and protection in COVID-19.HighlightsImmune microenvironment of SARS-CoV-2-infected lungs revealed by scRNA/TCR seqIncreased inflammatory FCN1+ macrophages are replacing FABP4+ macrophages in the BALF from severe COVID-19 patientsHighly expanded and functional competent tissue resident clonal CD8+ T cells in mild COVID-19 patientsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNoAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be available in GEO.